Goal
Sexual health
The peptides readers look up for sexual health, and whether each can be prescribed or compounded in the U.S. today. Every status below names the FDA document it rests on.
Prescribable now
The one peptide on this site approved for sexual desire. Two phase 3 trials support it for premenopausal women with low desire; the benefit they measured was modest and nausea was common. Read the PT-141 (bremelanotide) guide
Vyleesi (bremelanotide) injection, NDA 210557, approved June 21, 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Source:FDA document, read September 2026.
Sellers for sexual health
The licensed telehealths we have reviewed that prescribe PT-141 (bremelanotide) for sexual health. Each links to the seller and to our review of it.
Disclosure: This Peptide is reader-supported. No link on this site earns a commission today, so nothing here is a paid placement. How we make money.
- Synergy RxPrescribesPT-141 (bremelanotide)
Ordered by how many of these peptides each seller prescribes, then by name. A partnership never changes the order.
Research only
These are not on an FDA list that allows compounding, or we have not yet read their status. We cover the research on them and link no seller.
Kisspeptin
Research only
Kisspeptin-10 is in 503A Category 2 (bulk drug substances that raise significant safety risks), placed there September 29, 2023 and still listed in the May 14, 2026 update. FDA cites a possible risk of immunogenicity and peptide-related impurities, and says it has no, or only limited, safety information for the proposed routes.
Source:FDA document, read September 2026.Also:FDA, safety risks of certain bulk drug substances (Category 2 date and reason)
3 sellers we track list it; none publishes a price yet.
Research on sexual health
- Bremelanotide (PT-141): The FDA Approval and What the Trials ShowedBremelanotide is approved for low sexual desire in premenopausal women. Two phase 3 trials found a modest benefit, and 40% of women on it reported nausea.
- Bremelanotide Side Effects: Nausea, Blood Pressure and Skin DarkeningNausea in 40% of women, a brief blood pressure rise after every dose, and skin darkening that depends heavily on how often it is taken. What the Vyleesi label and trials report.
- Kisspeptin: What Human Studies Show About Libido and Reproductive HormonesSingle kisspeptin infusions changed brain responses to sexual cues in men and women with low desire, and raised reproductive hormones. It is not approved, and the FDA flags kisspeptin-10.
- PT 141 Dosage: The Vyleesi Label's 1.75 mg Dose and What Trials TestedThe label states one dose, 1.75 mg under the skin at least 45 minutes ahead, with limits of one a day and eight a month. Where that dose came from, and what it caused.
- PT 141 for Men: What the Erectile Dysfunction Trials FoundBremelanotide was first tested in men, then approved only for women. The male evidence is a few short lab studies of erections, and one larger trial its journal has flagged.
- PT-141 Nasal Spray: Why Intranasal Bremelanotide Was Dropped in TrialsBremelanotide was first tested as a nasal spray. Its developer dropped the route over blood pressure rises and uneven absorption, and the approved product is an injection.